Rheumatoid Arthritis Therapeutics in South-East Asia Market Segment Forecasts Up To USD 1.04 Billion By 2022: Radiant Insights,Inc
Summary
Rheumatoid Arthritis (RA) is a
chronic, progressive and currently incurable autoimmune disease that primarily
affects the joints. It is characterized by synovial inflammation and gradual
bone erosion over many years. Disease progression results in stiffness and
pain, especially in the hands and feet, which hinders mobility. Without
treatment, the disease leads to joint destruction and disability.
The chronic nature of the
disease, which requires ongoing treatment, and the relatively high annual cost
of therapy (ACoT) have made RA treatment a highly lucrative market.
View Full Report with TOC @ http://www.radiantinsights.com/research/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
The RA therapeutic market has
become very competitive due to the high number of new drug approvals.
Competition is fierce, particularly among TNF-α inhibitors, which dominate the
treatment market for RA patients who are refractory to traditional disease-modifying
anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a
clinical response when treated with TNF-α inhibitors. However, other targeted
programs, as well as newly marketed small-molecule DMARDs such as the Janus
kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace
ineffective TNF-α inhibitors. Recently published study results of Xeljanz have
shown a significant reduction in the risk of developing cardiac diseases such
as heart attack and stroke in patients with RA.
Despite the superior efficacy of
recently marketed therapies over traditional DMARD therapies, there is a need
to improve safety in the therapeutic landscape. Elevated rates of infection are
a frequent consequence of the immunosuppression involved in treatments, but
this is required to suppress the autoimmune responses responsible for the
symptoms of the condition. As a result, these biological therapies are not
recommended to patients who are susceptible to infection.
Request A Sample Copy of This Report at: http://www.radiantinsights.com/research/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022/request-sample
In addition, there is a need to
create biologics with more convenient and less invasive drug-delivery methods,
as all existing therapies are administered subcutaneously or intravenously.
These routes of administration are frequently associated with pain, rash, and
allergic reactions at the injection or infusion site, and in the case of
infusion flu-like illness, fever, chills, nausea, and headache. Therefore
convenient and safe administration without significant compromise of therapy
efficacy remains an unmet need.
Although the recently approved
drug Xeljanz is an orally administered small-molecule drug, indicated as a
second-line treatment for RA patients who have not shown an adequate response
to methotrexate, and as a third-line therapy for patients who have not
responded sufficiently to biologics, it carries a black-box warning in the US
due to the safety issues of serious infections and malignancy.
Scope
The current South-East Asia RA
market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra
(tocilizumab), an IL-6 receptor inhibitor.
·
What are
the competitive advantages of the existing novel drugs?
·
There are
over 450 active pipeline molecules, and most of the late-stage investigational
drug candidates feature improved dosing regimens and administration routes in
comparison to currently marketed products and combination therapies.
·
Which
classes of novel drugs are most prominent in the pipeline?
·
What is
the potential for pipeline products to address unmet needs in the RA market?
·
Analysis
of clinical trials since 2006 identified that the failure rates of RA molecules
were highest in Phase II, at 72.6%, with the overall attrition rate for RA
standing at 94.6%.
·
How do
failure rates vary by stage of development, molecule type, and molecular
target?
·
How do
other factors, such as average trial duration and trial size, influence the
costs and risks associated with product development?
·
Over the
2015-2022 forecast period, the South-East Asia RA therapeutics market is
expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over
$1.4 billion.
·
Which
markets make the most significant contribution to the current market size?
·
What are
the epidemiology trends in these markets?
·
Will new
market entrants lead to substantial changes in annual therapy costs?
·
How will
different treatment usage patterns impact growth in the eight assessed
South-East Asia markets?
·
Rising RA
prevalence population and the uptake of newer therapies will lead to
significant market growth over the forecast period, despite the launch of
biosimilars of blockbuster anti-TNFs.
·
Will the
launch of biosimilars or emerging pipeline molecules threaten the commercial
success of existing drugs?
Reasons to buy
This report will enable you to -
·
Understand
the clinical context of RA by considering epidemiology, symptoms, etiology and
pathophysiology, diagnosis, prognosis and treatment guidelines and options.
·
Identify
the therapeutic strategies, products, and companies that dominate the current
marketed products landscape and recognize gaps and areas of unmet need.
·
Identify
key pipeline trends in terms of molecule type, administration route, molecular
target, and novelty.
·
Consider
market opportunities and potential risks by examining trends in RA clinical
trial size, duration, and failure rate by stage of development, molecule type,
and molecular target.
·
Recognize
the late-stage pipeline molecules that have demonstrated strong therapeutic
potential in RA by examining clinical trial data and multi-scenario product
forecast projections.
·
Compare
treatment usage patterns, annual therapy costs, and market growth projections
for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand,
Vietnam, and Indonesia.
·
Discover
trends in licensing and co-development deals concerning RA products and
identify the major strategic consolidations that have shaped the commercial
landscape.
Browse Other Reports of This Category at: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to
meet their market research and business intelligence requirements. We assist
and facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant
Insights, Inc
Contact Person: Michelle
Thoras
Email:
sales@radiantinsights.com
Phone: (415) 349-0054
Address: 28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Comments
Post a Comment